When Novartis AG acquired the PCSK9 inhibitor Leqvio (inclisiran) in 2019 through the $9.7bn acquisition of The Medicines Company, CEO Vas Narasimhan outlined an ambitious business case for commercializing the twice-yearly, injectable cholesterol-lowering drug tied directly to reimbursement under Medicare Part B in the US.
Buy-And-Bill A Bust For Novartis's Leqvio?
The US commercial strategy for the PCSK9 inhibitor Leqvio was tied to reimbursement under Medicare Part B, but it hasn't developed the way Novartis envisioned.
